首页> 外文期刊>The Journal of Physiology >Acute and chronic effects of oestrogen on endothelial tissue-type plasminogen activator release in postmenopausal women.
【24h】

Acute and chronic effects of oestrogen on endothelial tissue-type plasminogen activator release in postmenopausal women.

机译:雌激素对绝经后妇女内皮组织型纤溶酶原激活剂释放的急性和慢性影响。

获取原文
获取原文并翻译 | 示例
           

摘要

The capacity of vascular endothelium to locally release tissue-type plasminogen activator (t-PA) represents an important endogenous defence mechanism against intravascular fibrin deposition and thrombosis. We determined the influence of chronic and acute oestrogen administration on endothelial t-PA release in postmenopausal women. Sixty-three healthy postmenopausal women were studied: 31 non-users (age 58 +/- 1 years) and 32 users of hormone replacement therapy, including oestrogen alone (ORT: 62 +/- 2 years; n = 15) and in combination with progesterone (HRT: 57 +/- 1 years; n = 17). Net endothelial t-PA release was determined in vivo, in response to intrabrachial infusions of bradykinin and sodium nitroprusside. To examine the acute effects of oestrogen on endothelial t-PA release, bradykinin and sodium nitroprusside dose-response curves were repeated in the presence of 17 beta-oestradiol in 20 of the 31 non-users. Net endothelial release of t-PA was ~30 % higher (P < 0.01) in women taking ORT (from 2.0 +/- 1.0 to 83.6 +/- 9.2 ng (100 ml tissue)-1 min-1) compared with those taking HRT (from 1.4 +/- 0.4 to 63.5 +/- 5.6 ng (100 ml tissue)-1 min-1) and those not taking supplementation (1.0 +/- 0.7 to 63.0 +/- 4.7 ng (100 ml tissue)-1 min-1). Intra-arterial infusion of 17 beta-oestradiol significantly potentiated bradykinin-induced t-PA release. Net endothelial release of t-PA was ~45 % higher (P < 0.01) after (from 1.0 +/- 0.8 to 87.4 +/- 9.9 ng (100 ml tissue)-1 min-1) versus before (1.2 +/- 0.6 to 60.8 +/- 5.6 ng (100 ml tissue)-1 min-1) acute 17 beta-oestradiol administration. Our results suggest that oestrogen has a direct modulatory effect on the capacity of the endothelium to release t-PA in healthy postmenopausal women. However, progesterone appears to oppose the favourable influence of oestrogen on endothelial fibrinolytic capacity.
机译:血管内皮局部释放组织型纤溶酶原激活剂(t-PA)的能力代表了重要的内源性防御机制,可抵抗血管内纤维蛋白沉积和血栓形成。我们确定了慢性和急性雌激素给药对绝经后妇女内皮t-PA释放的影响。对63名健康的绝经后妇女进行了研究:31位非使用者(年龄58 +/- 1岁)和32位激素替代疗法的使用者,包括单独的雌激素(ORT:62 +/- 2岁; n = 15)并结合使用黄体酮(HRT:57 +/- 1年; n = 17)。响应于臂内缓激肽和硝普钠的注入,在体内确定了内皮t-PA的净释放量。为了检查雌激素对内皮t-PA释放的急性影响,在31位非使用者中有20位存在17β-雌二醇的情况下,重复了缓激肽和硝普钠的剂量反应曲线。与服用ORT的女性(从100毫升组织的2.0 +/- 1.0至83.6 +/- 9.2 ng(100 ml组织)-1 min-1)相比,t-PA的净内皮释放高约30%(P <0.01) HRT(1.4 +/- 0.4至63.5 +/- 5.6 ng(100 ml组织)-1 min-1)和未服用补充剂(1.0 +/- 0.7至63.0 +/- 4.7 ng(100 ml组织)- 1分1)。动脉内输注17β-雌二醇可显着增强缓激肽诱导的t-PA释放。相对于之前(1.2 +/-),t-PA的净内皮释放量从(1.0 +/- 0.8到87.4 +/- 9.9 ng(100 ml组织)-1 min-1)后增加约45%(P <0.01) 0.6至60.8 +/- 5.6 ng(100 ml组织)-1 min-1)急性17β-雌二醇给药。我们的结果表明,雌激素对健康绝经后妇女的内皮释放t-PA的能力具有直接的调节作用。然而,孕酮似乎反对雌激素对内皮纤维蛋白溶解能力的有利影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号